Research validates therapeutic advantages of new cancer therapy

Posted on Tuesday, June 22nd, 2010

New research by scientists at The University of Texas Health Science Center at Houston and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

siRNA is a part of an innovative strategy to disrupt the activity of cancer-related genes that has broad applications to other diseases.

In the May 1 issue of Cancer Research, the scientists reported that a multistage nanovector system for the delivery of siRNA significantly lengthened the therapeutic effects of the treatment in two independent mouse models of advanced ovarian cancer.

The researchers reported that a single intravenous dose of siRNA targeting the EphA2 oncoprotein provided the same tumor shrinkage for three weeks as is now achieved by six doses over the same period.

“The multistage delivery system is revolutionary in that it allows the therapeutic payloads to cross the biological barriers in the body and reach their target. It further helps release agents over long periods of time directly into the bloodstream, which is unprecedented,” said Dr. Mauro Ferrari, chair of the Department of NanoMedicine and Biomedical Engineering. “We are very excited about the results of this paper, since it provides the first validation of the therapeutic advantages of the multistage delivery system in animal models of cancer.”

The multistage nanovector system is composed of nanoporous silicon carrier particles that are about 100 times smaller than a strand of hair, which can be loaded with tiny bubbles of fat called nanoliposomes containing siRNA. The system provides for the release of the nanoliposomes and their contents.

“This is an exciting development because RNA interference has worked well in an animal model but has such a short half-life that it requires frequent delivery. A three-week dosing period is much closer to the sustained dosing needed to properly test this therapy in clinical trials,” said Dr. Anil Sood, professor in M. D. Anderson’s Departments of Gynecological Oncology and Cancer Biology.

The multistage nanovector system was developed in Ferrari’s laboratory, and the liposomal siRNA was developed at M. D. Anderson.

“We have provided the first in vivo therapeutic validation of a novel, multistage siRNA delivery system for sustained gene silencing with broad applicability to pathologies,” said Dr. Takemi Tanaka, a co-first author and a research assistant professor of nanomedicine and biomedical engineering at the Medical School.

“EphA2 is an important target because it’s overexpressed in 70 percent of ovarian cancers and is strongly associated with poor survival and a higher likelihood of advanced or metastatic disease,” said Dr. Gabriel Lopez-Berestein, professor of experimental therapeutics at M. D. Anderson. “It’s also overexpressed in melanoma, breast and lung cancers with the same poor prospects for patients.”

The protein is not present in normal tissue and cannot be attacked using more traditional drug approaches.

Lopez-Berestein; Sood, co-director of M. D. Anderson’s Center for RNA Interference and Non-Coding RNA; and Ferrari are the senior authors.

Study contributors from UTHealth include Dr. René Nieves-Alicea; Aman Preet, Singh Mann, Dr. Xuewu Liu, Rohan Bhavane, Jianhua Gu, Jean Fakhoury, and Dr. Biana Godin. M. D. Anderson contributors include Dr. Lingegowda Mangala, co-first author; Dr. Edna Mora; Hee-Dong Han; Dr. Pablo Vivas-Mejia; Mian Shahzad; Chunhua Lu; Koji Matsuo; Dr. Rebecca Stone; and Dr. Alpa Nick. Ciro Chiappini, a graduate research assistant at The University of Texas at Austin, also contributed to the study.

The study, which is titled “Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles,” received support from the Department of Defense, the State of Texas Emerging Technology Fund, National Aeronautics and Space Administration, the Ovarian Cancer Research Fund Program Project Development Grant, The University of Texas M. D. Anderson Cancer Center Ovarian Cancer Specialized Program of Research Excellence, the National Institutes of Health, the Zarrow Foundation, the Betty Ann Asche Murray Distinguished Professorship, the Baylor WRHR Grant and the GCF Molly-Cade Ovarian Cancer Research Grant, and the Alliance for NanoHealth.

— Rob Cahill, Office of Institutional Advancement, Media Relations

---

For assistance, please call UT Physicians at 1-888-4UT-DOCS (1-888-488-3627). Access directories of our clinics by clicking on Clinics & Locations.